End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive

Gradual Decline From $12bn Peak Expected

 
• By Andrew McConaghie
  
New BMS logo
The gradual entry of generics gives BMS extra time to replace Revlimid's lost revenues • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Therapy Areas